[1] The company particularly focuses on niche drugs for small patient populations.
[2] Products include the ADHD medicine, Desoxyn (brand name for methamphetamine hydrochloride), and vigabatrin, an anticonvulsant that inhibits the catabolism of GABA and is indicated for epilepsy and substance abuse.
[citation needed] In 2003, Sanofi sold its interests in stanozolol, Methylphenobarbital, and Dimercaptosuccinic acid to Ovation.
[4] In 2008, the Federal Trade Commission sued Ovation in Minnesota federal district court over its 2006 acquisition of NeoProfen, a treatment for a congenital heart defect in newborns known as patent ductus arteriosus.
[7] In 2010, a district court judge ruled that the FTC had not proved its case.